Stock Market Reviews

DNA (Ginkgo Bioworks Holdings, Inc.) News

Get the latest news, insights, and market updates on DNA (Ginkgo Bioworks Holdings, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program
  Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects Agency for Health's (ARPA-H) Engineering of Immune Cell Inside the Body (EMBODY) program. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D. The partnership aims to develop in vivo chimeric antigen receptor (CAR) therapies for autoimmune diseases, leveraging Ginkgo's expertise in RNA construct design and immune cell engineeri
  Oct 23, 2025 - $DNA
• Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights
  In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.78, marking a -2.67% move from the previous day.
  Oct 22, 2025 - $DNA
• Ginkgo Bioworks Holdings, Inc. (DNA) Dips More Than Broader Market: What You Should Know
  In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $15.12, indicating a -4.49% shift from the previous trading day.
  Oct 16, 2025 - $DNA
• Looking at the Narrative for Ginkgo Bioworks After Recent Analyst and Strategy Updates
  Ginkgo Bioworks Holdings has seen its consensus analyst price target rise from $11.33 per share to $12.00 per share. This reflects a modest but noteworthy vote of confidence from the market. The upward revision comes amid shifting expectations following recent performance updates, as analysts weigh the company’s progress against lingering uncertainties. Read on to find out how you can stay ahead of ongoing changes in the stock’s evolving narrative. What Wall Street Has Been Saying Following...
  Oct 10, 2025 - $DNA
• Ginkgo Bioworks Holdings, Inc. (DNA) Registers a Bigger Fall Than the Market: Important Facts to Note
  Ginkgo Bioworks Holdings, Inc. (DNA) reached $15.24 at the closing of the latest trading day, reflecting a -5.28% change compared to its last close.
  Oct 9, 2025 - $DNA
• Ginkgo Bioworks Holdings, Inc. (DNA) Outpaces Stock Market Gains: What You Should Know
  Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $16.14, signifying a +1.06% move from its prior day's close.
  Oct 3, 2025 - $DNA
• Ginkgo Bioworks Holdings Stock Scores RS Rating Upgrade
  Ginkgo Bioworks Holdings stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Tuesday. Is Ginkgo Bioworks Holdings Stock A Buy? Ginkgo Bioworks Holdings stock recently retook its 50-day moving line and is trying to complete a cup without handle with a 15.48 buy point.
  Sep 30, 2025 - $DNA
• Ginkgo Bioworks Holdings, Inc. (DNA) Advances While Market Declines: Some Information for Investors
  The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $12.35, representing a +2.66% change from its previous close.
  Sep 23, 2025 - $DNA
• Ginkgo Datapoints and Apheris Launch Antibody Developability Consortium
  BOSTON, September 04, 2025--Ginkgo Bioworks announced a series of new initiatives to accelerate the application of artificial intelligence in biologics drug discovery.
  Sep 4, 2025 - $DNA
• Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions
  Ginkgo Bioworks (NYSE: DNA) today released the following notice:
  Aug 29, 2025 - $DNA